MAIA Biotechnology (MAIA) Current Assets (2021 - 2026)
MAIA Biotechnology (MAIA) posted quarterly Current Assets of $35.3 million for Q1 2026, up 197.72% year-over-year from $11.9 million in Q1 2025, and up 264.0% quarter-over-quarter from $9.7 million in Q4 2025.
MAIA Biotechnology (MAIA) Current Assets (2021 - 2026) Analysis & Trends
MAIA Biotechnology (MAIA) has reported Current Assets for 6 consecutive years, with $35.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets rose 197.72% year-over-year to $35.3 million; the TTM figure through Mar 2026 stood at $35.3 million (up 197.72% YoY), while the FY2025 annual figure was $9.7 million, down 4.44% from the prior year.
- Current Assets grew to $35.3 million in Q1 2026 per MAIA's latest filing, from $9.7 million in the prior quarter.
- Across five years, Current Assets topped out at $35.3 million in Q1 2026 and bottomed at $6.6 million in Q3 2023.
- Historically, Current Assets has averaged $11.7 million across 5 years, with a median of $10.0 million in 2023.
- Annual changes were most pronounced in 2023 — Current Assets sank 55.12% — and 2026, when it surged 197.72%.
- MAIA Biotechnology's Current Assets stood at $11.8 million in 2022, then plunged by 35.94% to $7.6 million in 2023, then jumped by 34.22% to $10.2 million in 2024, then retreated by 4.44% to $9.7 million in 2025, then surged by 264.0% to $35.3 million in 2026.
- Business Quant data shows MAIA's Current Assets at $35.3 million in Q1 2026, $9.7 million in Q4 2025, and $11.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.76 Bn |
| 10 | MAIA Biotechnology | 84.50 Mn | 56.91 Mn | - | 28.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 28.24 Mn |
| Mar 31, 2026 | 35.32 Mn |
| Dec 31, 2025 | 9.70 Mn |
| Sep 30, 2025 | 11.75 Mn |
| Jun 30, 2025 | 11.04 Mn |
| Mar 31, 2025 | 11.86 Mn |
| Dec 31, 2024 | 10.15 Mn |
| Sep 30, 2024 | 9.24 Mn |
| Jun 30, 2024 | 12.02 Mn |
| Mar 31, 2024 | 8.70 Mn |
| Dec 31, 2023 | 7.56 Mn |
| Sep 30, 2023 | 6.63 Mn |
| Jun 30, 2023 | 9.78 Mn |
| Mar 31, 2023 | 8.33 Mn |
| Dec 31, 2022 | 11.81 Mn |
| Sep 30, 2022 | 14.78 Mn |
| Jun 30, 2022 | 8.61 Mn |
| Dec 31, 2021 | 10.67 Mn |